On the public citation graph
The consensus molecular classification of muscle-invasive bladder cancer
0 signed · 203 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/path.4886openalex-snapshot
Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification
inferredcites →https://doi.org/10.1016/j.ccell.2016.05.004openalex-snapshot
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
inferredcites →https://doi.org/10.1016/j.ccell.2017.08.005openalex-snapshot
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency
inferredcites →https://doi.org/10.1016/j.ccr.2014.01.009openalex-snapshot
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
inferredcites →https://doi.org/10.1016/j.cell.2017.09.007openalex-snapshot
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
inferredcites →https://doi.org/10.1016/j.cell.2018.03.022openalex-snapshot
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
inferredcites →https://doi.org/10.1016/j.celrep.2014.10.035openalex-snapshot
Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes
inferredcites →https://doi.org/10.1016/j.eururo.2015.07.021openalex-snapshot
On Molecular Classification of Bladder Cancer: Out of One, Many
inferredcites →https://doi.org/10.1016/j.eururo.2017.03.010openalex-snapshot
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset
inferredcites →https://doi.org/10.1016/j.eururo.2017.03.030openalex-snapshot
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
inferredcites →https://doi.org/10.1016/j.eururo.2018.08.027openalex-snapshot
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
inferredcites →https://doi.org/10.1016/j.eururo.2018.09.003openalex-snapshot
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
inferredcites →https://doi.org/10.1016/j.eururo.2019.02.017openalex-snapshot
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability
inferredcites →https://doi.org/10.1016/j.ijrobp.2004.03.005openalex-snapshot
Role of cell cycle in mediating sensitivity to radiotherapy
inferredcites →https://doi.org/10.1016/j.ydbio.2013.12.028openalex-snapshot
Identification of ELF3 as an early transcriptional regulator of human urothelium
inferredcites →https://doi.org/10.1016/s0140-6736(16)00561-4openalex-snapshot
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)32365-6openalex-snapshot
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
inferredcites →https://doi.org/10.1038/cdd.2017.10openalex-snapshot
Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium
inferredcites →https://doi.org/10.1038/nature25501openalex-snapshot
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
inferredcites →https://doi.org/10.1038/nbt.2203openalex-snapshot
Absolute quantification of somatic DNA alterations in human cancer
inferredcites →https://doi.org/10.1038/ncomms3612openalex-snapshot
Inferring tumour purity and stromal and immune cell admixture from expression data
inferredcites →https://doi.org/10.1038/ng.3458openalex-snapshot
Regulators of genetic risk of breast cancer identified by integrative network analysis
inferredcites →https://doi.org/10.1038/ng1061openalex-snapshot
Identifying distinct classes of bladder carcinoma using microarrays
inferredcites →https://doi.org/10.1038/nm.3967openalex-snapshot
The consensus molecular subtypes of colorectal cancer
inferredcites →https://doi.org/10.1038/nrc.2016.126openalex-snapshot
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
inferredcites →https://doi.org/10.1038/nrc3817openalex-snapshot
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
inferredcites →https://doi.org/10.1038/s41598-017-11291-0openalex-snapshot
Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer
inferredcites →https://doi.org/10.1038/s41598-018-22126-xopenalex-snapshot
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
inferredcites →https://doi.org/10.1073/pnas.1120605109openalex-snapshot
Three differentiation states risk-stratify bladder cancer into distinct subtypes
inferredcites →https://doi.org/10.1073/pnas.1318376111openalex-snapshot
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
inferredcites →https://doi.org/10.1093/annonc/mdx371.013openalex-snapshot
Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
inferredcites →https://doi.org/10.1093/annonc/mdy410openalex-snapshot
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
inferredcites →https://doi.org/10.1093/jnci/djx243openalex-snapshot
Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas
inferredcites →https://doi.org/10.1093/jrr/rrw007openalex-snapshot
The impact of hypoxia and its modification of the outcome of radiotherapy
inferredcites →https://doi.org/10.1126/scitranslmed.3008970openalex-snapshot
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
inferredcites →https://doi.org/10.1137/040608635openalex-snapshot
Graph Clustering Via a Discrete Uncoupling Process
inferredcites →https://doi.org/10.1158/0008-5472.can-09-4213openalex-snapshot
Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2409openalex-snapshot
Bladder Cancer Outcome and Subtype Classification by Gene Expression
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-0077-topenalex-snapshot
A Molecular Taxonomy for Urothelial Carcinoma
inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0229openalex-snapshot
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
inferredcites →https://doi.org/10.1172/jci91190openalex-snapshot
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
inferredcites →https://doi.org/10.1186/1471-2105-14-7openalex-snapshot
GSVA: gene set variation analysis for microarray and RNA-Seq data
inferredcites →https://doi.org/10.1186/gb-2011-12-4-r41openalex-snapshot
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
inferredcites →https://doi.org/10.1186/s12920-015-0101-5openalex-snapshot
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems
inferredcites →https://doi.org/10.1186/s13059-016-1070-5openalex-snapshot
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
inferredcites →https://doi.org/10.1200/jco.2014.60.7341openalex-snapshot
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
inferredcites →https://doi.org/10.1200/jco.2016.67.2048openalex-snapshot
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.3510openalex-snapshot
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.3511openalex-snapshot
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
inferredcites →https://doi.org/10.1214/07-aoas101openalex-snapshot
On testing the significance of sets of genes
inferredcites →https://doi.org/10.17615/za09-dk57openalex-snapshot
Comprehensive molecular characterization of urothelial bladder carcinoma
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/9781119707677.ch30openalex-snapshot
Molecular Pathology of Bladder Cancer
inferred← citeshttps://doi.org/10.1002/cac2.12129openalex-snapshot
Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer
inferred← citeshttps://doi.org/10.1002/hep.31092openalex-snapshot
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
inferred← citeshttps://doi.org/10.1002/ijc.32556openalex-snapshot
Proteome‐based classification of Nonmuscle Invasive Bladder Cancer
inferred← citeshttps://doi.org/10.1002/ijc.33794openalex-snapshot
Single‐cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer
inferred← citeshttps://doi.org/10.1002/ijc.33809openalex-snapshot
A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer—Stromal gene expressions show higher prognostic values than intrinsic tumor genes
inferred← citeshttps://doi.org/10.1002/ijc.34715openalex-snapshot
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
inferred← citeshttps://doi.org/10.1002/mc.23232openalex-snapshot
SlowN‐acetylation as a possible contributor to bladder carcinogenesis
inferred← citeshttps://doi.org/10.1002/mc.23844openalex-snapshot
Predictive Value of Neutrophil Extracellular Traps in Neoadjuvant Chemotherapy for Muscle‐Invasive Bladder Cancer
inferred← citeshttps://doi.org/10.1002/path.5318openalex-snapshot
Molecular pathology of the luminal class of urothelial tumors
inferred← citeshttps://doi.org/10.1002/path.5813openalex-snapshot
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer
inferred← citeshttps://doi.org/10.1002/path.6060openalex-snapshot
Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis
inferred← citeshttps://doi.org/10.1002/path.6062openalex-snapshot
The Lund taxonomy for bladder cancer classification – from gene expression clustering to cancer cell molecular phenotypes, and back again
inferred← citeshttps://doi.org/10.1002/tox.24038openalex-snapshot
Radiogenomics uncovers an interplay between angiogenesis and clinical outcomes in bladder cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-70646-3_5openalex-snapshot
Risk Stratification of Patients: Risk Tables and Assessment – NMIBC and MIBC
inferred← citeshttps://doi.org/10.1007/978-3-030-84432-5_9openalex-snapshot
Biomarkers in Urinary Tract and Male Genital System Carcinomas
inferred← citeshttps://doi.org/10.1007/s00120-019-01046-2openalex-snapshot
Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie
inferred← citeshttps://doi.org/10.1007/s00120-019-0934-1openalex-snapshot
Molekulares Tumorboard Uroonkologie aus pathologischer Sicht
inferred← citeshttps://doi.org/10.1007/s00292-019-00645-2openalex-snapshot
Sitzungsbericht der Arbeitsgemeinschaft Uropathologie der Deutschen Gesellschaft für Pathologie 2019
inferred← citeshttps://doi.org/10.1007/s00292-019-00688-5openalex-snapshot
Therapieprädiktive Biomarker des Harnblasenkarzinoms
inferred← citeshttps://doi.org/10.1007/s00292-019-0606-3openalex-snapshot
Prädiktive Biomarker in der onkologischen Uropathologie
inferred← citeshttps://doi.org/10.1007/s11523-024-01047-yopenalex-snapshot
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/s11596-023-2731-8openalex-snapshot
ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer
inferred← citeshttps://doi.org/10.1007/s12032-022-01885-8openalex-snapshot
Combined single-cell RNA-seq and bulk RNA-seq to analyze the expression and role of TREM2 in bladder cancer
inferred← citeshttps://doi.org/10.1007/s12094-024-03400-zopenalex-snapshot
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
inferred← citeshttps://doi.org/10.1016/b978-0-443-15504-8.00003-xopenalex-snapshot
Artificial intelligence in personalized medicine: application of genomics to influence therapy decisions
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.11.014openalex-snapshot
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
inferred← citeshttps://doi.org/10.1016/j.ebiom.2020.102858openalex-snapshot
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
inferred← citeshttps://doi.org/10.1016/j.euf.2019.10.016openalex-snapshot
Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
inferred← citeshttps://doi.org/10.1016/j.eururo.2019.05.025openalex-snapshot
Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?
inferred← citeshttps://doi.org/10.1016/j.eururo.2022.01.026openalex-snapshot
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
inferred← citeshttps://doi.org/10.1016/j.purol.2019.08.268openalex-snapshot
Spécificités épidémiologiques, pathologiques et pronostiques du cancer de la vessie chez les patients âgés
inferred← citeshttps://doi.org/10.1016/j.urolonc.2019.04.010openalex-snapshot
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
inferred← citeshttps://doi.org/10.1016/j.urolonc.2019.10.013openalex-snapshot
Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.urolonc.2022.10.031openalex-snapshot
25 years International Bladder Cancer Network (IBCN): The past, the present, and the future
inferred← citeshttps://doi.org/10.1016/s0302-2838(22)00171-3openalex-snapshot
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
inferred← citeshttps://doi.org/10.1016/s0302-2838(22)00327-xopenalex-snapshot
Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA
inferred← citeshttps://doi.org/10.1038/s41379-021-00776-zopenalex-snapshot
Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications
inferred← citeshttps://doi.org/10.1038/s41388-020-01465-yopenalex-snapshot
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
inferred← citeshttps://doi.org/10.1038/s41388-023-02876-3openalex-snapshot
The urothelial gene regulatory network: understanding biology to improve bladder cancer management
inferred← citeshttps://doi.org/10.1038/s41416-021-01488-6openalex-snapshot
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
inferred← citeshttps://doi.org/10.1038/s41416-022-01703-yopenalex-snapshot
TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1038/s41416-022-01799-2openalex-snapshot
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
inferred← citeshttps://doi.org/10.1038/s41416-023-02513-6openalex-snapshot
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
inferred← citeshttps://doi.org/10.1038/s41416-024-02598-7openalex-snapshot
Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer
inferred← citeshttps://doi.org/10.1038/s41417-022-00438-5openalex-snapshot
Identification of an immune gene-associated prognostic signature in patients with bladder cancer
inferred← citeshttps://doi.org/10.1038/s41417-024-00725-3openalex-snapshot
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells
inferred← citeshttps://doi.org/10.1038/s41467-021-22465-wopenalex-snapshot
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1038/s41467-022-29441-yopenalex-snapshot
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
inferred← citeshttps://doi.org/10.1038/s41571-023-00826-2openalex-snapshot
Progress in systemic therapy for advanced-stage urothelial carcinoma
inferred← citeshttps://doi.org/10.1038/s41571-024-00869-zopenalex-snapshot
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
inferred← citeshttps://doi.org/10.1038/s41585-020-00386-5openalex-snapshot
The complex genetics of epigenetics in urothelial carcinomas
inferred← citeshttps://doi.org/10.1038/s41585-020-0339-3openalex-snapshot
Exploring the molecular basis of sexual dimorphism in bladder cancer
inferred← citeshttps://doi.org/10.1038/s41585-023-00773-8openalex-snapshot
Urine biomarkers in bladder cancer — current status and future perspectives
inferred← citeshttps://doi.org/10.1038/s41585-023-00784-5openalex-snapshot
From mucosal infection to successful cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41585-023-00805-3openalex-snapshot
Bioinformatics in urology — molecular characterization of pathophysiology and response to treatment
inferred← citeshttps://doi.org/10.1038/s41585-023-00806-2openalex-snapshot
The sex gap in bladder cancer survival — a missing link in bladder cancer care?
inferred← citeshttps://doi.org/10.1038/s41585-023-00847-7openalex-snapshot
Molecular profile of bladder cancer progression to clinically aggressive subtypes
inferred← citeshttps://doi.org/10.1038/s41585-024-00885-9openalex-snapshot
Preclinical models of bladder cancer: BBN and beyond
inferred← citeshttps://doi.org/10.1038/s41585-024-00901-yopenalex-snapshot
CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1038/s41585-024-00951-2openalex-snapshot
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer
inferred← citeshttps://doi.org/10.1038/s41585-025-01066-yopenalex-snapshot
Mechanisms and implications of epithelial cell plasticity in the bladder
inferred← citeshttps://doi.org/10.1038/s41588-024-01674-1openalex-snapshot
A combinatorial genetic strategy for exploring complex genotype–phenotype associations in cancer
inferred← citeshttps://doi.org/10.1038/s41591-021-01317-6openalex-snapshot
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
inferred← citeshttps://doi.org/10.1038/s41591-025-03802-8openalex-snapshot
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
inferred← citeshttps://doi.org/10.1038/s41598-020-76904-7openalex-snapshot
Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
inferred← citeshttps://doi.org/10.1038/s41598-023-39827-7openalex-snapshot
Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response
inferred← citeshttps://doi.org/10.1038/s41746-025-01560-yopenalex-snapshot
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
inferred← citeshttps://doi.org/10.1038/s43018-024-00822-0openalex-snapshot
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
inferred← citeshttps://doi.org/10.1080/14737140.2020.1807334openalex-snapshot
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
inferred← citeshttps://doi.org/10.1093/med/9780198854371.003.0012openalex-snapshot
Muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1097/cji.0000000000000525openalex-snapshot
RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000033605openalex-snapshot
Bioinformatics identification and validation of aging‑related molecular subtype and prognostic signature in breast cancer
inferred← citeshttps://doi.org/10.1097/mou.0000000000000782openalex-snapshot
Fibroblast growth factor receptors across urothelial carcinoma landscape
inferred← citeshttps://doi.org/10.1097/mou.0000000000001020openalex-snapshot
Brief update of the new WHO classification for urothelial carcinoma
inferred← citeshttps://doi.org/10.1097/mou.0000000000001025openalex-snapshot
Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis
inferred← citeshttps://doi.org/10.1097/mou.0000000000001126openalex-snapshot
Use of genomic markers to improve epidemiologic and clinical research in urology
inferred← citeshttps://doi.org/10.1097/mou.0000000000001177openalex-snapshot
Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine
inferred← citeshttps://doi.org/10.1097/mou.0000000000001183openalex-snapshot
Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer
inferred← citeshttps://doi.org/10.1097/mou.0000000000001309openalex-snapshot
Artificial intelligence in muscle-invasive bladder cancer: opportunities, challenges, and clinical impact
inferred← citeshttps://doi.org/10.1097/pai.0000000000001272openalex-snapshot
Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification
inferred← citeshttps://doi.org/10.1097/pap.0000000000000252openalex-snapshot
Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy
inferred← citeshttps://doi.org/10.1097/pap.0000000000000309openalex-snapshot
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers
inferred← citeshttps://doi.org/10.1097/pap.0000000000000383openalex-snapshot
Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors
inferred← citeshttps://doi.org/10.1097/pap.0000000000000430openalex-snapshot
Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in Clinical Decision-making
inferred← citeshttps://doi.org/10.1097/pap.0000000000000432openalex-snapshot
Glandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates
inferred← citeshttps://doi.org/10.1097/pap.0000000000000433openalex-snapshot
Updates on Urinary Bladder Tumors With Neuroendocrine Features
inferred← citeshttps://doi.org/10.1097/pas.0000000000001453openalex-snapshot
Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer
inferred← citeshttps://doi.org/10.1097/pas.0000000000002053openalex-snapshot
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4
inferred← citeshttps://doi.org/10.1101/2021.09.02.458778openalex-snapshot
FGFR3 activating mutations induce luminal-like papillary bladder tumor formation and favor a male gender bias
inferred← citeshttps://doi.org/10.1101/2022.02.04.22270000openalex-snapshot
The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blocking
inferred← citeshttps://doi.org/10.1101/2022.03.31.486514openalex-snapshot
Bladder cancer organoids as a functional system to model different disease stages and therapy response
inferred← citeshttps://doi.org/10.1101/868190openalex-snapshot
PPARγ is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities
inferred← citeshttps://doi.org/10.1111/bju.14802openalex-snapshot
Molecular landscape of carcinoma invading bladder muscle: does patient age matter?
inferred← citeshttps://doi.org/10.1111/bju.15188openalex-snapshot
Preoperative detection of Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection…
inferred← citeshttps://doi.org/10.1111/bju.16191openalex-snapshot
Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer
inferred← citeshttps://doi.org/10.1111/bju.16325openalex-snapshot
The SUB ‐urothelial DUrvalumab InjEction ‐1 ( SUBDUE ‐1) trial: first‐in‐human trial in patients with bladder cancer
inferred← citeshttps://doi.org/10.1111/his.14038openalex-snapshot
The expanding molecular and mutational landscape of nested variant of urothelial carcinoma
inferred← citeshttps://doi.org/10.1111/his.14764openalex-snapshot
What's new in WHO fifth edition – urinary tract
inferred← citeshttps://doi.org/10.1111/his.15130openalex-snapshot
Associations of TACSTD2/ TROP2 and NECTIN‐4/ NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts
inferred← citeshttps://doi.org/10.1111/iju.14082openalex-snapshot
Predictive biomarkers for drug response in bladder cancer
inferred← citeshttps://doi.org/10.1111/iju.14686openalex-snapshot
Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab
inferred← citeshttps://doi.org/10.1111/iju.14689openalex-snapshot
Programmed cell death‐ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma
inferred← citeshttps://doi.org/10.1111/iju.14719openalex-snapshot
Editorial Comment to Programmed cell death‐ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma
inferred← citeshttps://doi.org/10.1111/iju.15335openalex-snapshot
Epigenetic alterations in urothelial bladder cancer associated with disease outcomes
inferred← citeshttps://doi.org/10.1111/iju.70167openalex-snapshot
Editorial Comment on “Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins”
inferred← citeshttps://doi.org/10.1111/pin.13060openalex-snapshot
Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor‐associated immune cell status in muscle‐invasive bladder cancer
inferred← citeshttps://doi.org/10.1155/2022/8213321openalex-snapshot
Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer
inferred← citeshttps://doi.org/10.1158/0008-5472.can-20-2336openalex-snapshot
Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-21-1807openalex-snapshot
NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody–Drug Conjugate
inferred← citeshttps://doi.org/10.1186/s12859-022-04980-9openalex-snapshot
Deep learning approach for cancer subtype classification using high-dimensional gene expression data
inferred← citeshttps://doi.org/10.1186/s12885-023-11182-wopenalex-snapshot
A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer
inferred← citeshttps://doi.org/10.1186/s12967-024-05685-8openalex-snapshot
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1186/s13073-019-0669-zopenalex-snapshot
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis
inferred← citeshttps://doi.org/10.1371/journal.pone.0221785openalex-snapshot
Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0243935openalex-snapshot
Development and validation of a NanoString BASE47 bladder cancer gene classifier
inferred← citeshttps://doi.org/10.1556/650.2019.31559openalex-snapshot
A húgyhólyag urothelialis daganatainak molekuláris alcsoportbeosztása és annak klinikai vonatkozásai
inferred← citeshttps://doi.org/10.15562/bmj.v12i2.4541openalex-snapshot
Interobserver agreement and the role of smoothelin immunostain in the evaluation of Muscularis Propria (MP) invasion of Bladder Urothelial Carcinoma (BUC)
inferred← citeshttps://doi.org/10.17305/bb.2023.9242openalex-snapshot
Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16
inferred← citeshttps://doi.org/10.18053/jctres.07.202103.009openalex-snapshot
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.18231/j.achr.2025.003openalex-snapshot
Clinicopathological study of urothelial neoplasms based on WHO Classification & its utility in patient management
inferred← citeshttps://doi.org/10.20517/2394-4722.2021.171openalex-snapshot
Biomarkers for therapy selection in metastatic urothelial cancer
inferred← citeshttps://doi.org/10.20903/zpopov-2022openalex-snapshot
ПРЕДИЗВИЦИ ВО ХИРУРГИЈАТА НА УРОГЕНИТАЛНИОТ СИСТЕМ, ТРАНСПЛАНТАЦИЈАТА И МЕДИЦИНАТА
inferred← citeshttps://doi.org/10.21037/tau-20-1039openalex-snapshot
Urinary extracellular vesicles: a rising star in bladder cancer management
inferred← citeshttps://doi.org/10.21037/tau-20-1109openalex-snapshot
TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
inferred← citeshttps://doi.org/10.21037/tau-20-1185openalex-snapshot
A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?
inferred← citeshttps://doi.org/10.21037/tau-20-1327openalex-snapshot
Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
inferred← citeshttps://doi.org/10.21037/tau-20-1472openalex-snapshot
Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review
inferred← citeshttps://doi.org/10.21037/tau-2019-mibc-12openalex-snapshot
Update on bladder cancer molecular subtypes
inferred← citeshttps://doi.org/10.21037/tau-21-158openalex-snapshot
Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients
inferred← citeshttps://doi.org/10.21037/tau-21-887openalex-snapshot
A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy
inferred← citeshttps://doi.org/10.21037/tau-22-43openalex-snapshot
Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes
inferred← citeshttps://doi.org/10.21037/tau.2020.03.13openalex-snapshot
Tumor heterogeneity in muscle-invasive bladder cancer
inferred← citeshttps://doi.org/10.21037/tcr-20-1243openalex-snapshot
The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma
inferred← citeshttps://doi.org/10.21037/tcr-20-2169openalex-snapshot
Variant histology in bladder cancer: diagnostic and clinical implications
inferred← citeshttps://doi.org/10.21037/tcr-20-2257openalex-snapshot
Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer—narrative review
inferred← citeshttps://doi.org/10.25040/ntsh2020.01.09openalex-snapshot
MOLECULAR SUBTYPES OF MUSCULAR INVASIVE BLADDER CANCER
inferred← citeshttps://doi.org/10.26779/2522-1396.2020.1-2.92openalex-snapshot
Molecular subtypes of a bladder cancer: evolution of classifications and clinical significance
inferred← citeshttps://doi.org/10.31265/usps.161openalex-snapshot
Better prognostic markers for nonmuscle invasive papillary urothelial carcinomas
inferred← citeshttps://doi.org/10.3233/blc-190257openalex-snapshot
Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications
inferred← citeshttps://doi.org/10.3390/cancers12071784openalex-snapshot
Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
inferred← citeshttps://doi.org/10.3390/ijms21165670openalex-snapshot
Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications
inferred← citeshttps://doi.org/10.3390/ijms23116305openalex-snapshot
Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
inferred← citeshttps://doi.org/10.3410/f.739140172.793581483openalex-snapshot
Faculty Opinions recommendation of circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex.
inferred← citeshttps://doi.org/10.3906/biy-2107-72openalex-snapshot
Classification of bladder cancer cell lines according to regulon activity
inferred← citeshttps://doi.org/10.4149/bll_2024_46openalex-snapshot
Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence
inferred← citeshttps://doi.org/10.54112/bcsrj.v2023i1.622openalex-snapshot
DIAGNOSTIC ACCURACY OF T2 WEIGHTED IMAGING AND GADOLINIUM ENHANCED MRI IN DIAGNOSIS AND STAGING OF URINARY BLADDER CARCINOMA TAKING HISTOPATHOLOGY AS GOLD STANDARDS
inferred← citeshttps://doi.org/10.5505/tjo.2021.2884openalex-snapshot
Epigenetics in Bladder Cancer: A Review of the Literature
inferred← citeshttps://doi.org/10.70675/3635da7az5e15z4aaaz890cz02e6ace799ecopenalex-snapshot
Identification of APOBEC-Associated Frequent Mutations and Characterization of FGFR3-Driven Signaling Pathways in Bladder Cancer
inferred← citeshttps://doi.org/10.7150/jca.93023openalex-snapshot
Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance
inferred← citeshttps://doi.org/10.7150/thno.103175openalex-snapshot
TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.